Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced it will present three posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 6-10, 2024 in Houston, Texas. The presentations will include:
1. Updated clinical data from the ongoing Phase 1/2 ABILITY-1 Study of MDNA11, a long-acting 'beta-enhanced not-alpha' IL-2 super-agonist, in patients with advanced or metastatic solid tumors.
2. New preclinical data on MDNA113, a novel first-in-class, masked, tumor-targeted bifunctional anti-PD1-IL-2 Superkine.
3. Preclinical data on Medicenna's IL-2 agonists in glioblastoma.
The full abstracts will be available on the SITC 2024 website, and posters will be accessible on Medicenna's website after the conference.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) ha annunciato che presenterà tre poster al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC) che si svolgerà dal 6 al 10 novembre 2024 a Houston, Texas. Le presentazioni includeranno:
1. Dati clinici aggiornati dello studio Fase 1/2 ABILITY-1 su MDNA11, un super-agonista IL-2 'beta-enhanced not-alpha' a lunga durata d'azione, in pazienti con tumori solidi avanzati o metastatici.
2. Nuovi dati preclinici su MDNA113, un innovativo bifunzionale anti-PD1-IL-2 Superchino di nuova concezione, mirato ai tumori.
3. Dati preclinici sugli agonisti dell'IL-2 di Medicenna nel glioblastoma.
Gli abstract completi saranno disponibili sul sito web della SITC 2024 e i poster saranno accessibili sul sito di Medicenna dopo la conferenza.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) anunció que presentará tres pósters en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC) del 6 al 10 de noviembre de 2024 en Houston, Texas. Las presentaciones incluirán:
1. Datos clínicos actualizados del estudio en curso Fase 1/2 ABILITY-1 de MDNA11, un super-agonista IL-2 'beta-enhanced not-alpha' de acción prolongada, en pacientes con tumores sólidos avanzados o metastásicos.
2. Nuevos datos preclínicos sobre MDNA113, un innovador bifuncional anti-PD1-IL-2 Superquino de primera clase.
3. Datos preclínicos sobre los agonistas de IL-2 de Medicenna en glioblastoma.
Los resúmenes completos estarán disponibles en el sitio web de SITC 2024, y los pósters estarán accesibles en el sitio web de Medicenna después de la conferencia.
메디센나 테라퓨틱스 코프(상장: MDNA, OTCQB: MDNAF)는 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 열리는 제39회 암 면역요법 학회(SITC)에서 세 개의 포스터를 발표할 것이라고 발표했습니다. 발표 내용은 다음과 같습니다:
1. 진행 중인 1/2상 ABILITY-1 연구에 대한 최신 임상 데이터로, 이는 진행성 또는 전이성 고형 종양 환자의 장기 작용 '베타 강화 비 알파' IL-2 슈퍼 아고니스트 MDNA11에 대한 것입니다.
2. 새로운 전임상 데이터로, MDNA113라는 첫 번째 클래스의 차단된 종양 표적 이중기능성 항-PD1-IL-2 슈퍼카인이 다뤄집니다.
3. 메디센나의 신경아교세포증에 대한 IL-2 아고니스트에 대한 전임상 데이터입니다.
전체 초록은 SITC 2024 웹사이트에서 확인 가능하며, 포스터는 회의 후 메디센나 웹사이트에서 열람할 수 있습니다.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) a annoncé qu'elle présentera trois affiches lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC) qui se tiendra du 6 au 10 novembre 2024 à Houston, au Texas. Les présentations incluront :
1. Des données cliniques mises à jour de l'étude en cours Phase 1/2 ABILITY-1 sur MDNA11, un super-agoniste IL-2 'beta-enhanced not-alpha' à action prolongée, chez des patients atteints de tumeurs solides avancées ou métastatiques.
2. De nouvelles données précliniques sur MDNA113, un nouvel anti-PD1-IL-2 Superkine bifonctionnel ciblé sur les tumeurs, de première classe.
3. Des données précliniques sur les agonistes IL-2 de Medicenna dans le glioblastome.
Les résumés complets seront disponibles sur le site Web du SITC 2024, et les affiches seront accessibles sur le site de Medicenna après la conférence.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) gab bekannt, dass sie drei Poster auf dem 39. Jahrestreffen der Society for Immunotherapy of Cancer (SITC) vom 6. bis 10. November 2024 in Houston, Texas, präsentieren wird. Die Präsentationen umfassen:
1. Aktualisierte klinische Daten aus der laufenden Phase 1/2 ABILITY-1-Studie zu MDNA11, einem langwirksamen 'beta-enhanced not-alpha' IL-2 Super-Agonisten bei Patienten mit fortgeschrittenen oder metastatischen soliden Tumoren.
2. Neue präklinische Daten zu MDNA113, einem neuartigen bifunktionalen, maskierten, tumor-targetierten Anti-PD1-IL-2 Superkine der ersten Klasse.
3. Präklinische Daten zu Medicennas IL-2 Agonisten bei Glioblastom.
Die vollständigen Abstracts werden auf der SITC 2024-Website verfügbar sein, und die Poster werden nach der Konferenz auf Medicennas Website zugänglich sein.
- Presentation of updated clinical data from Phase 1/2 ABILITY-1 Study of MDNA11
- Showcasing new preclinical data on MDNA113, a novel first-in-class Superkine
- Presenting preclinical data on IL-2 agonists in glioblastoma
- None.
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors
Preclinical data on MDNA113, Medicenna's first-in-class, masked, tumor-targeted bifunctional anti-PD1-IL-2 Superkine, and on its IL-2 agonists in glioblastoma, will also be presented
TORONTO and HOUSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present three posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”), taking place from November 6 – 10, 2024 in Houston, Texas.
The Company will present updated clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (“IL-2”) super-agonist, as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) in patients with advanced or metastatic solid tumors. In addition, new pre-clinical data on the Company’s MDNA113, a novel first-in-class, masked, tumor-targeted bifunctional anti-PD1-IL-2 Superkine, and on Medicenna’s IL-2 agonists in glioblastoma, will also be presented at the conference.
Details for the poster presentations are as follows:
Title: Results from ABILITY-1 monotherapy dose escalation and ongoing monotherapy
expansion with MDNA11, a long-acting ‘beta-enhanced not-alpha’ IL-2 Superkine, in patients
with advanced solid tumors
Abstract Number: 684
Presentation Date: Saturday, November 9, 2024
Title: MDNA113 is a conditionally activatable anti-PD1-IL-2SK with a removable IL-13 dual masking/tumor-targeting domain to limit systemic immune stimulation while maximizing anti-tumor response
Abstract Number: 961
Session Date: Friday, November 8, 2024
Title: Stimulation of IL-2 signaling with highly selective IL-2R agonists enhances immune
effector cell response in mouse and patient-derived glioblastomas
Abstract Number: 963
Session Date: Friday, November 8, 2024
The full text of the abstracts will be available on the SITC 2024 website. Following the conclusion of the SITC 2024 Meeting, a copy of the posters will be available on the “Scientific Presentations” page of Medicenna’s website.
About MDNA11
MDNA11 is an intravenously administered, long-acting ‘beta-enhanced not-alpha’ IL-2 Superkine specifically engineered to overcome the shortcomings of aldesleukin and other next generation IL-2 variants by preferentially activating immune effector cells (CD8+ T and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. These unique proprietary features of the IL-2 Superkine have been achieved by incorporating seven specific mutations and genetically fusing it to a recombinant human albumin scaffold to improve the pharmacokinetic (PK) profile and pharmacological activity of MDNA11 due to albumin’s natural propensity to accumulate in highly vascularized sites, in particular tumor and tumor draining lymph nodes. MDNA11 is currently being evaluated in the Phase 1/2 ABILITY-1 study as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
About the ABILITY-1 Study
The ABILITY-1 study (NCT05086692) is a global, multi-center, open-label study that assesses the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MDNA11 as monotherapy or in combination with pembrolizumab (KEYTRUDA®). In the combination dose escalation of the Phase 2 study, approximately 6-12 patients are expected to be enrolled and administered ascending doses of MDNA11 intravenously once every two weeks in combination with pembrolizumab. This portion of the study includes patients with a wide range of solid tumors with the potential for susceptibility to immune modulating therapeutics. Upon identification of an appropriate dose regimen for combination, the study will proceed to a combination dose expansion cohort.
About MDNA113
MDNA113 is a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL2 Superkine with exceptionally high affinity for IL-13Rα2 without binding to the functional IL-13R⍺1. IL-13Rα2 is overexpressed in a wide range of solid tumors, including cold tumors with minimal to no expression in normal tissues. IL-13Rα2 expressing tumors also have abundant matrix metalloprotease in the tumor microenvironment that may efficiently activate MDNA113. IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate cancer, pancreatic cancer, ovarian cancer, liver cancer, breast cancer and brain cancer, with an annual world-wide incidence of over 2 million.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts, such as statements on the therapeutic potential and safety profile of MDNA11 and MDNA113. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Christina Cameron
Investor Relations, Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com
FAQ
What will Medicenna Therapeutics (MDNAF) present at the SITC 2024 Annual Meeting?
When and where will the SITC 2024 Annual Meeting take place?
What is MDNA11 and what is its current development stage for Medicenna (MDNAF)?